Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKEX: 6990) reported on July 15, 2026, that a prespecified interim analysis of the Phase III OptiTROP-Lung06 study met its primary endpoint of progression-free survival for sacituzumab tirumotecan plus pembrolizumab in first-line PD-L1-negative, locally advanced or metastatic non-squamous non-small cell lung cancer. An independent data monitoring committee concluded that the combination produced a statistically significant and clinically meaningful improvement over pembrolizumab with pemetrexed and platinum chemotherapy. The disclosure remains a company-reported topline result, not a regulatory approval, and it did not include the hazard ratio, median progression-free survival, response data or detailed safety rates.
This is a consequential test because the experimental regimen was not compared with a weak or outdated control. It was tested against an established chemoimmunotherapy approach for patients whose tumours have a PD-L1 tumour proportion score below 1% and who do not have actionable driver alterations that would direct treatment toward a targeted therapy.
The result therefore raises a more commercially and clinically important possibility than simply adding another late-line antibody-drug conjugate to the lung cancer pipeline. Sacituzumab tirumotecan could potentially replace the conventional cytotoxic chemotherapy component of a first-line regimen while retaining pembrolizumab, although the size, durability and tolerability of that benefit cannot yet be judged from the limited disclosure.
What did OptiTROP-Lung06 actually establish against first-line chemoimmunotherapy?
OptiTROP-Lung06 is a randomised, open-label, multicentre Phase III study registered as NCT06711900. The public trial record lists an estimated enrolment of 432 participants and identifies the study as active but no longer recruiting. Eligible patients had previously untreated locally advanced or metastatic non-squamous non-small cell lung cancer, PD-L1 tumour proportion score below 1%, and no genomic alteration for which an approved targeted treatment would be appropriate.
Participants were assigned to sacituzumab tirumotecan plus pembrolizumab or to pembrolizumab combined with pemetrexed and either carboplatin or cisplatin. The primary endpoint was progression-free survival assessed by blinded independent central review, while overall survival and safety were among the secondary measures. Central review is an important design strength because it reduces the risk that knowledge of treatment allocation will influence radiographic progression assessments in an otherwise open-label trial.
Kelun-Biotech said the progression-free survival improvement was statistically significant and clinically meaningful at the prespecified interim analysis. It also reported a positive trend in overall survival and said the safety profile was consistent with earlier sacituzumab tirumotecan studies, with no new safety signal identified. Those statements establish that the study crossed its predefined progression-free survival boundary, but they do not reveal how large the benefit was, how long patients were followed, or whether the emerging survival trend is likely to mature into a statistically persuasive result.
That missing information matters. A hazard ratio, confidence interval, median progression-free survival in each arm, landmark progression-free survival rates and duration-of-response data are needed to understand whether the result represents a modest delay in progression or a more substantial change in disease control. The company’s conclusion that the difference was clinically meaningful is encouraging, but the full dataset will allow clinicians and regulators to make their own assessment.
Why is beating pembrolizumab plus pemetrexed and platinum a demanding clinical test?
Pembrolizumab with pemetrexed and platinum chemotherapy is an established first-line regimen for metastatic non-squamous non-small cell lung cancer without EGFR or ALK genomic aberrations. In patients with PD-L1 expression below 1%, pembrolizumab monotherapy is not the relevant benchmark because low PD-L1 expression reduces the rationale for relying on immune checkpoint inhibition alone. Chemotherapy helps provide early tumour control while pembrolizumab contributes an immune-mediated component.
OptiTROP-Lung06 therefore asked whether a TROP2-directed antibody-drug conjugate could replace pemetrexed and platinum chemotherapy rather than merely supplement an underpowered regimen. Sacituzumab tirumotecan carries a belotecan-derived topoisomerase I inhibitor payload to TROP2-expressing tumour cells through a bifunctional linker. Its average drug-to-antibody ratio is 7.4, and the released payload is designed to damage tumour-cell DNA and exert a bystander effect in the tumour microenvironment.
The mechanistic case for pairing an antibody-drug conjugate with immune checkpoint inhibition is plausible, but mechanism alone does not prove clinical synergy. The randomised progression-free survival result is more important because it tests the complete regimen against active therapy. If the full data show a sizeable benefit with an acceptable safety and quality-of-life profile, the study could support a first-line approach that exchanges conventional chemotherapy for a targeted delivery system. It should not yet be described as a new standard of care because survival, safety and regulatory review remain unresolved.
Can earlier OptiTROP-Lung05 data strengthen confidence without answering Lung06?
The latest result follows the positive Phase III OptiTROP-Lung05 study in PD-L1-positive advanced non-small cell lung cancer without targetable genomic alterations. That trial randomised 413 patients to sacituzumab tirumotecan plus pembrolizumab or pembrolizumab alone. At a median follow-up of 10.5 months, median progression-free survival had not been reached with the combination and was 5.7 months with pembrolizumab, producing a hazard ratio of 0.35.
OptiTROP-Lung05 has been presented at the 2026 American Society of Clinical Oncology Annual Meeting and published in The Lancet, giving the sacituzumab tirumotecan and pembrolizumab strategy a peer-reviewed Phase III foundation in the PD-L1-positive population. The National Medical Products Administration has accepted the related new indication application in China and placed it into priority review.
The two studies are complementary, but they are not interchangeable. OptiTROP-Lung05 enrolled patients with PD-L1 tumour proportion score of at least 1% and used pembrolizumab alone as its control. OptiTROP-Lung06 enrolled the PD-L1-negative non-squamous population and used a more intensive pembrolizumab plus chemotherapy control. Differences in biomarker status, histology, comparator treatment and potentially baseline risk prevent the numerical result from one trial being projected onto the other.
Even so, positive randomised results across both PD-L1-defined segments strengthen the argument that activity is not confined to tumours with readily detectable PD-L1 expression. The full OptiTROP-Lung06 analysis must show whether that biological breadth is accompanied by a clinically worthwhile margin over chemoimmunotherapy.
What safety details will determine whether replacing chemotherapy with a TROP2 ADC is worthwhile?
The phrase “no new safety signal” means that the monitoring committee did not identify an unexpected toxicity pattern during the disclosed follow-up. It does not mean that the combination was less toxic than the control or that serious adverse events were uncommon. That distinction is especially important when a proposed first-line regimen is competing with a familiar therapy whose adverse-event profile and supportive-care requirements are already well understood.
In OptiTROP-Lung05, grade 3 or higher treatment-emergent adverse events occurred in 55% of patients receiving sacituzumab tirumotecan plus pembrolizumab and 31% receiving pembrolizumab alone. Earlier studies of sacituzumab tirumotecan combinations have identified haematological toxicities including neutrophil, white blood cell and haemoglobin reductions among the more important high-grade events. Those findings provide context for clinical monitoring, but they cannot establish the relative safety outcome in OptiTROP-Lung06 because its control arm also contained cytotoxic chemotherapy.
The useful comparison will include grade 3 or higher adverse events, serious events, treatment-related deaths, dose reductions, interruptions and permanent discontinuations in both arms. Rates of neutropenia, anaemia, gastrointestinal and mucosal toxicity, interstitial lung disease or pneumonitis, and immune-mediated events will require close examination. Patient-reported outcomes will also matter because avoiding platinum-based treatment is meaningful only if the replacement regimen preserves or improves daily functioning without introducing a comparable burden through a different toxicity profile.
Treatment logistics form another part of the value equation. The sacituzumab tirumotecan regimen requires repeated intravenous ADC dosing alongside pembrolizumab, so it does not eliminate infusion-centre use or laboratory monitoring. Any claim of practical simplification will depend on infusion time, supportive medication, dose delays and maintenance duration as much as on the absence of platinum chemotherapy.
How does this result change the competitive picture after uneven TROP2 ADC lung-cancer trials?
The TROP2 antibody-drug conjugate class has produced mixed lung cancer results, which makes a positive study against active first-line therapy more notable. Gilead Sciences’ sacituzumab govitecan did not meet the overall survival endpoint in the previously treated Phase III EVOKE-01 trial. In June 2026, Merck & Co., Inc. and Gilead discontinued the Phase III EVOKE-03 study of sacituzumab govitecan plus pembrolizumab in previously untreated metastatic non-small cell lung cancer with PD-L1 expression of at least 50% after progression-free survival failed to reach statistical significance and the probability of a significant overall survival result was judged low.
Datopotamab deruxtecan, developed by Daiichi Sankyo Company, Limited and AstraZeneca plc, has secured United States accelerated approval for previously treated EGFR-mutated non-small cell lung cancer and is being studied in first-line combinations. These programmes confirm that TROP2 is a commercially important target, but they also show that ADCs directed at the same antigen cannot be assumed to deliver the same efficacy or safety. Antibody characteristics, linker stability, payload, dosing, tumour biology and treatment setting all influence outcomes.
OptiTROP-Lung06 does not establish direct superiority over another TROP2 ADC because no head-to-head trial was conducted. It does, however, give sacituzumab tirumotecan a differentiated positive Phase III signal in a broad first-line, PD-L1-negative non-squamous population. That distinction may become strategically important if the effect size and survival follow-up remain persuasive.
What must happen before China’s NMPA can consider a new first-line sac-TMT indication?
Kelun-Biotech said it plans to communicate with the Center for Drug Evaluation of the National Medical Products Administration using the OptiTROP-Lung06 results. That is the next regulatory step, not confirmation that an application has been submitted, accepted or approved. The regulator will need the complete efficacy and safety package, details of the interim analysis, manufacturing information and the proposed wording of any new indication.
Sacituzumab tirumotecan already has four approved indications in China across triple-negative breast cancer, hormone receptor-positive and HER2-negative breast cancer, and EGFR-mutated non-squamous non-small cell lung cancer settings. The first two approved indications disclosed by the company have entered China’s National Reimbursement Drug List. The pending PD-L1-positive first-line lung cancer application is separate and is already under priority review.
A future PD-L1-negative indication would broaden the China lung cancer franchise into patients without actionable driver alterations and with low PD-L1 expression, but the boundaries of the eventual label will depend on the submitted population and regulatory assessment. Approval in China would not automatically authorise the regimen elsewhere.
Kelun-Biotech retains rights to develop, manufacture and commercialise sacituzumab tirumotecan in Greater China. Merck holds exclusive rights outside Greater China and is running a large global TroFuse programme with 17 ongoing Phase III studies across multiple tumour types. The global programme provides substantial optionality, but each jurisdiction and indication still requires an appropriate evidence package. OptiTROP-Lung06 is an important validation event for the asset, not a substitute for Merck’s global registrational work.
Why did Kelun-Biotech shares surge, and what expectations are now built into the valuation?
Kelun-Biotech shares rose sharply after the Phase III disclosure. The stock traded at HK$553.50 during the July 15 session, about 11.1% above the previous close of HK$498.20, and approached the upper end of its HK$339.60 to HK$581.00 52-week range. At that intraday level, the shares were approximately 15.5% above their July 8 close and 32% above the June 15 close.
The reaction indicates that investors viewed the result as a meaningful expansion opportunity rather than a routine pipeline update, although a same-day move cannot be attributed solely to one announcement with absolute certainty. Sentiment also reflects the wider sacituzumab tirumotecan franchise, existing China approvals, Merck’s global commitment and Kelun-Biotech’s recently completed HK$2.7 billion H-share placing.
The valuation now carries higher expectations for a favourable regulatory path and commercially useful full data. That creates a familiar biotechnology tension: the topline result reduces one important efficacy risk, but missing effect-size, survival and safety details still leave room for the market’s interpretation to move in either direction when the dataset is presented.
Which OptiTROP-Lung06 data will decide whether the topline result changes practice?
The next meaningful disclosure should include the progression-free survival hazard ratio and confidence interval, median progression-free survival in both groups, landmark rates, objective response rate, duration of response and the maturity of overall survival follow-up. Prespecified subgroup results will be important for assessing consistency across baseline characteristics, while information on patients with stable brain metastases could help clarify the regimen’s relevance to a common clinical complication of advanced lung cancer.
Detailed adverse-event and discontinuation tables will show whether the ADC combination genuinely offers a favourable benefit-risk balance against platinum, pemetrexed and pembrolizumab. Quality-of-life data, subsequent treatment patterns and longer overall survival follow-up will determine whether delaying radiographic progression translates into a benefit that patients and clinicians can meaningfully recognise.
For Kelun-Biotech, the immediate milestones are scientific presentation of the complete dataset and formal regulatory engagement in China. OptiTROP-Lung06 has passed its first decisive test against a credible standard-of-care control. Whether it can support a broader first-line label and alter treatment practice will depend on the numbers that were not included in the topline announcement.
